Abstract
To determine the median effective dose (ED50) and the 95% effective dose (ED95) of ciprofol combined with sufentanil for inhibiting the tracheal intubation response in female patients and to evaluate the hemodynamic stability and adverse events associated with this drug combination. This was a prospective dose-finding study using an up-and-down sequential allocation method. A total of 30 female patients undergoing general anesthesia surgeries between November 2024 and December 2024 were enrolled. Patients were administered ciprofol for induction, with an initial dose of 0.4 mg/kg and subsequent doses adjusted based on the presence or absence of an intubation response. The primary outcome was the ED50 of ciprofol, with secondary outcomes including patient baseline characteristics, hemodynamic parameters, and adverse events. The ED50 and ED95 of ciprofol for inhibiting tracheal intubation response were 0.318 mg/kg and 0.496 mg/kg, respectively. Patients with a positive tracheal intubation response had significantly higher heart rates and mean arterial pressures, as well as a higher incidence of hypertension and body movement. The ED50 and ED95 of ciprofol combined with sufentanil for suppressing the response to tracheal intubation in female patients were 0.318 mg/kg and 0.496 mg/kg, respectively.